tbuckley/cabot-search huggingface dataset:
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Authors: Gerhardt Attard, Laura Murphy, Noel W Clarke, William Cross, Robert J Jones, Christopher C Parker, Silke Gillessen, Adrian Cook, Chris Brawley, Claire L Amos, Nafisah Atako, Cheryl Pugh, Michelle Buckner, Simon Chowdhury, Zafar Malik, J Martin Russell, Clare Gilson, Hannah Rush, Jo Bowen, Anna Lydon, Ian Pedley, Joe M O'Sullivan, Alison Birtle, Joanna Gale, Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzoueb, Omi Parikh, Angus Robinson, Isabel Syndikus, James Wylie, Anjali Zarkar, George Thalmann, Johann S de Bono, David P Dearnaley, Malcolm D Mason, Duncan Gilbert, Ruth E Langley, Robin Millman, David Matheson, Matthew R Sydes, Louise C Brown, Mahesh K B Parmar, Nicholas D James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Zafar Malik, Anjali Zarkar, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Jacob Tanguay, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, Dakshinamoorthy Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, Mohammed Kagzi, Prantik Das, Carmel Pezaro, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan McLaren, Nishi Gupta, Denise Sheehan, Stergios Boussios, Henry Taylor, John Graham, Carla Perna, Lucinda Melcher, Warren Grant, Katherine Hyde, Ami Sabharwal, Uschi Hofmann, Robert Dealey, Neil McPhail, Robert Brierly, Simon Brown, Lisa Capaldi, Norma Sidek, Peter Whelan, Thiagarajan Sreenivasan, Peter Robson, Alison Falconer, Sarah Rudman, Sindu Vivekanandan, Vinod Mullessey, Sarah Needleman, Maria Vilarino-Varela, Vincent Khoo, Karen Tipples, Mehran Afshar, Alison Falconer, Patryk Brulinski, Vijay Sangar, Clive Peedell, Ashraf Azzabi, Peter Hoskin, Viwod Mullassery, Santhanam Sundar, Yakhub Khan, Ruth Conroy, Andrew Protheroe, Judith Carser, Paul Rogers, Lisa Capaldi, Kathryn Tarver, Stephanie Gibbs, Mohammad Muneeb Khan, Mohan Hingorani, Ashraf Azzabi, Simon Crabb, Manal Alameddine, Neeraj Bhalla, Caroline Manetta, Robert Hughes, John Logue, Darren Leaning, Salil Vengalil, Ashraf Azzabi, Daniel Ford, Georgina Walker, Ahmed Shaheen, Omar Khan, Andrew Chan, Imtiaz Ahmed, Serena Hilman, Fiona Douglas, Anil Kumar, Anna Tran, Sangeeta Paisey, Ian Sayers, Lisa Capaldi, Ashok Nikapota, David Bloomfield, Tim Porter, Joji Joseph, Cyrill Rentsch, Ricardo Pereira Mestre, Enrico Roggero, Jörg Beyer, Markus Borner, Raeto Strebel, Dominik Berthold, Daniel Engeler, Hubert John, Razvan Popescu, Donat Durr
Journal: The Lancet (2021)
Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastoma—A New Standard of Care?
Authors: Matthias A. Karajannis, Audrey Mauguen, Kim Kramer
Journal: JAMA Oncology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
JAAD Case Reports Article List
Authors: Travis Dowdle, Jeannie Nguyen, Ashley Sturgeon, Michelle Tarbox, Cloyce Stetson, Connor Stonesifer, Syed Ba, George Husain, Stephanie Niedt, Danielle Perna, Jordan Jones, Courtney Schadt, G Safadi, Kasey Smith, Shahzeb Hassan, Viki Patel, Michael Viglione, Scott Zahner, Bina Kassamali, Scott Ba, Anthony Elman, Avery Lachance, Joseph Merola, Mohsen Dourra, Shiab Mussad, Robert Singer, Ramiz Hamid, Rachel Yang, Girish Munavalli, Jose Ricardo, Shari Lipner, Jeffrey Bubley, Maher Alharthi, Jack Arbiser, Catherine Xie, Michal Kidacki, Nan Ring, Gauri Panse, Jonathan Leventhal, Christopher Nguyen, Swaminathan Iyer, Roberto Miranda, Carlos Torres-Cabala, Jonathan Curry, Penny Fang, Valencia Thomas, Auris Huen, Andrea Rea, Alexis Anderson, Ata Moshiri, Kelly Paulson, John Thompson, Andrea Kalus, Vivien Chen, Naiem Issa, Fernanda Schmidt, Melissa Leeolou, P Perrault, Dharshan Sivaraj, Anne Lynn, S Chang, Kellen Chen, Artem Trotsyuk, Jagannath Padmanabhan, Geoffrey Gurtner, Arjun Bal, Adam Sorensen, Sharon Ondreyco, James Hunter, Audrey Pyle, Travis Rutherford, Stephanie Vandergriff, Shani Torres Rodriguez, Arturo Shastri, Mahendra Kura, Naresh Ramteke, Supreet Dhillon, Madison Hill, Risa Jampel, Lucie Van Esbeen, Pierre-Paul Roquet-Gravy, Ali Malik, Penelope Skopis, Clinton Enos, Addie Walker, Kiran Motaparthi, Angelia Stepien, Charles Perniciaro, Pearl Kwong, Juan Rosario-Collazo, Karthik Krishnamurthy, Hayley Braun, Justin Cheeley, Fnu Nutan, Heloisa De Carvalho, Harrison Ngo, Stamatina Danielides, Victoria Madray, Katherine Braunlich, Jordan Said, Cesar Ba, Christine Virgen, Corey Lian, Joseph Cutler, Nicole Merola, Katherine Jicha, David Ba, Jayson Wang, Luis Miedema, Julie Dang, Catherine Mccuaig, Deana Funaro, Catherine Morin, Haya Raef, Sarina Elmariah, Charussri Leeyaphan, Brian Rankin, Richard Haber, Hannah Thompson, Brian King, Brian Link, Vincent Liu, Claire Le Calve, Henry Abi-Rached, Claire Vicentini, Cyril Maire, Emmanuel Delaporte, Serge Mordon, Delphine Staumont-Salle ´, Laurent Mortier, Renajd Rrapi, Sidharth Chand, Rebecca Gaffney, Jennifer Lo, Jeffrey Smith, Fan Xia, Steven Chen, Lyn Duncan, Ruth Foreman, Rebecca Hartman, Mai Hoang, Adriano Piris, Andrew Walls, Daniela Kroshinsky, Nicole Negbenebor, Aubrey Hess, Christopher Dimarco, Leslie Robinson-Bostom, Hongmei Li, Oluwakemi Onajin, Omar Sangueza, Austin Burns, Mark Marchitto, Mamta Jhaveri, Jun Kang, Sima Rozati, Rodrigo Rossi Balbinotti, Fernanda Santos Grossi, Amanda Vilaverde Perez, Mariana Sbaraini, Luciana Borges Chagas, Aline Tregnago, Janete Vettorazzi, Camilla Vassallo, Valentina Ruffo, Di Calabria, Eugenio Isoletta, Simona Biscarini, Alessandro Filippo, Valeria Brazzelli
Journal: Journal of the American Academy of Dermatology (2021)
Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine
Authors: Xiaonan Zheng, Hang Xu, Xianyanling Yi, Tianyi Zhang, Qiang Wei, Hong Li, Jianzhong Ai
Journal: Molecular Cancer (2021)

Prostate adenocarcinoma (PRAD) is a leading cause of death among men. Messenger ribonucleic acid (mRNA) vaccine presents an attractive approach to achieve satisfactory outcomes; however, tumor antigen screening and vaccination candidates show a bottleneck in this field. We aimed to investigate the tumor antigens for mRNA vaccine development and immune subtypes for choosing appropriate patients for vaccination. We identified eight overexpressed and mutated tumor antigens with poor prognostic value of PRAD, including KLHL17, CPT1B, IQGAP3, LIME1, YJEFN3, KIAA1529, MSH5 and CELSR3. The correlation of those genes with antigen-presenting immune cells were assessed. We further identified three immune subtypes of PRAD (PRAD immune subtype [PIS] 1-3) with distinct clinical, molecular, and cellular characteristics. PIS1 showed better survival and immune cell infiltration, nevertheless, PIS2 and PIS3 showed cold tumor features with poorer prognosis and higher tumor genomic instability. Moreover, these immune subtypes presented distinguished association with immune checkpoints, immunogenic cell death modulators, and prognostic factors of PRAD. Furthermore, immune landscape characterization unraveled the immune heterogeneity among patients with PRAD. To summarize, our study suggests KLHL17, CPT1B, IQGAP3, LIME1, YJEFN3, KIAA1529, MSH5 and CELSR3 are potential antigens for PRAD mRNA vaccine development, and patients in the PIS2 and PIS3 groups are more suitable for vaccination.
Impact of cancer metabolism on therapy resistance – Clinical implications
Authors: Ana Cristina Gonçalves, Elena Richiardone, Joana Jorge, Bárbara Polónia, Cristina P.R. Xavier, Iris Chiara Salaroglio, Chiara Riganti, M. Helena Vasconcelos, Cyril Corbet, Ana Bela Sarmento-Ribeiro
Journal: Drug Resistance Updates (2021)
Highlights from this issue
Journal: Thorax (2021)

The Triumvirate 'If everyone in the music business were brutally honest about what their intentions were then you could sort things out, but it's all smoke and mirrors.'So said Noel Gallagher of Oasis.In this month's Airwaves, we discuss music, smoke and mirrors and of course respiratory science! CIGARETTES AND ALCOHOLIn the early nineties, Oasis famously sang: "…all I need are cigarettes and alcohol…" But will the fags protect the Gallaghers against death from COVID-19?In the early stages of the pandemic some epidemiological studies concluded that smoking was associated with lower risks of COVID-19 mortality.In this month's Thorax (see page 65) Clift and colleagues explode this myth with a Mendelian randomisation study.The study cohort comprises almost 300 000 white British participants from the UK Biobank, with data on smoking exposure.In addition, the researchers identified genetic proxies for smoking initiation and smoking heaviness.The team used record linkage to collate outcome data from COVID-19 testing results, hospital admissions, and death certificates.The authors report a positive association between smoking and risk of COVID-19-related death.Genetically predicted smoking heaviness was strongly associated with death from COVID-19.The authors suggest that the "table 2 fallacy" may explain the previous studies which suggested that smoking protects.In a linked editorial (see page 7), Laverty and Millet suggest that the pandemic should focus our minds on tobacco control and point out that tobacco kills more people per year than have died as a result of COVID-19.The Triumvirate agree that tobacco control should be our top priority.As Oasis put it: "You gotta make it happen".
47MO Metabolic intervention during CAR T-cell manufacturing improves persistence and antitumor efficacy
Authors: M. Wenes, A. Jaccard, T. Wyss, N. Maldonado-Pérez, S-T. Teoh, A. Lepez, F. Renaud, F. Franco, P. Waridel, B. Tschumi, L. Zhang, A. Donda, F. Martin, D. Migliorini, S. Lunt, P-C. Ho, P. Romero
Journal: Annals of Oncology (2021)
A nationwide study evaluating the association of autoimmune bullous diseases and acquired haemophilia: description of clinical and prognostic features
Authors: Alexis Barranca, Sébastien Debarbieux, Emmanuelle Tancrède‐Bohin, Clémence Saillard, Bruno Sassolas, Sophie Voisin, Françoise Fortenfant, Chloe Bost, Ségolène Claeyssens‐Donadel, Pascal Joly, Christophe Bedane, Cristina Bulai‐Livideanu, Carle Paul, Maria Polina Konstantinou
Journal: British Journal of Dermatology (2021)

-
Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer
Authors: Veerle H. Groen, Karin Haustermans, Floris J. Pos, Cédric Draulans, Sofie Isebaert, Evelyn M. Monninkhof, Robert J. Smeenk, Martina Kunze-Busch, Johannes C.J. de Boer, Jochem van der Voort van Zijp, Linda G.W. Kerkmeijer, Uulke A. van der Heide
Journal: European Urology (2021)
Liposome delivery to the brain with rapid short-pulses of focused ultrasound and microbubbles
Authors: Sophie V. Morse, Aishwarya Mishra, Tiffany G. Chan, Rafael T. M. de Rosales, James J. Choi
Journal: Journal of Controlled Release (2021)

Liposomes are clinically used drug carriers designed to improve the delivery of drugs to specific tissues while minimising systemic distribution. However, liposomes are unable to cross the blood-brain barrier (BBB) and enter the brain, mostly due to their large size (ca. 100 nm). A noninvasive and localised method of delivering liposomes across the BBB is to intravenously inject microbubbles and apply long pulses of ultrasound (pulse length: >1 ms) to a targeted brain region. Recently, we have shown that applying rapid short pulses (RaSP) (pulse length: 5 μs) can deliver drugs with an improved efficacy and safety profile. However, this was tested with a relatively smaller 3-kDa molecule (dextran). In this study, we examine whether RaSP can deliver liposomes to the murine brain in vivo. Fluorescent DiD-PEGylated liposomes were synthesized and injected intravenously alongside microbubbles. The left hippocampus of mice was then sonicated with either a RaSP sequence (5 μs at 1.25 kHz in groups of 10 ms at 0.5 Hz) or a long pulse sequence (10 ms at 0.5 Hz), with each pulse having a 1-MHz centre frequency (0.35 and 0.53 MPa). The delivery and distribution of the fluorescently-labelled liposomes were assessed by fluorescence imaging of the brain sections. The safety profile of the sonicated brains was assessed by histological staining. RaSP was shown to locally deliver liposomes across the BBB at 0.53 MPa with a more diffused and safer profile compared to the long pulse ultrasound sequence. Cellular uptake of liposomes was observed in neurons and microglia, while no uptake within astrocytes was observed in both RaSP and long pulse-treated brains. This study shows that RaSP allows a targeted and safe delivery of liposomal drugs into the murine brain with potential to deliver drugs into neuronal and glial targets.
Magnetic covalent organic framework nanospheres-based miRNA biosensor for sensitive glioma detection
Authors: Dong Liang, Xiaoyi Zhang, Yi Wang, Taotao Huo, Min Qian, Yibo Xie, Wenshuai Li, Yunqiu Yu, Wei Shi, Qianqian Liu, Junle Zhu, Chun Luo, Zhijuan Cao, Rongqin Huang
Journal: Bioactive Materials (2021)

Sensitive detection and accurate diagnosis/prognosis of glioma remain urgent challenges. Herein, dispersed magnetic covalent organic framework nanospheres (MCOF) with uniformed Fe3O4 nano-assembly as cores and high-crystalline COF as shells were prepared by monomer-mediated in-situ interface growth strategy. Based on the unique interaction between MCOF and hairpin DNA, a fluorescent signal amplified miRNA biosensor was constructed. It could realize the sensitive detection of miRNA-182 in different matrixes, where the detection limit, linearity range and determination coefficient (R2) in real blood samples reached 20 fM, 0.1 pM-10 pM and 0.991, respectively. Also, it possessed good stability and precision as observed from the low intra-day/inter-day RSD and high extraction recovery. As a result, it could quantify miRNA-182 in serum of glioma patients, the concentration of which was significantly higher than that of healthy people and obviously decreased after surgery. Finally, a proof-of-concept capillary chip system using this biosensor was proposed to realize the visualized detection of miRNA-182 in microsample. These findings suggest a robust way for sensitive detection and accurate diagnosis/prognosis of glioma.
Correction: Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study
Authors: Pradeep S. Chauhan, Kevin Chen, Ramandeep K. Babbra, Wenjia Feng, Nadja Pejovic, Armaan Nallicheri, Peter K. Harris, Katherine Dienstbach, Andrew Atkocius, Lenon Maguire, Faridi Qaium, Jeffrey J. Szymanski, Brian C. Baumann, Li Ding, Dengfeng Cao, Melissa A. Reimers, Eric H. Kim, Zachary L. Smith, Vivek K. Arora, Aadel A. Chaudhuri
Journal: PLoS Medicine (2021)

[This corrects the article DOI: 10.1371/journal.pmed.1003732.].
Abstract 17062: Reversible Golimumab Induced Cardiomyopathy - First Reported Case Report
Authors: Mian Tanveer Ud Din, Michael Nestasie, John Balacko, Craig Alpert
Journal: Circulation (2021)

Case Presentation: An 80 year old female with medical history of hypertension, diabetes mellitus, chronic atrial fibrillation presented with four weeks of lower extremity edema and dyspnea. Notably, she had also been taking Golimumab for 6 months for Rheumatoid Arthritis (RA). Vital signs on presentations were: Temp:99 F, HR: 140bpm, BP: 105/64, oxygen saturation of 88% on room air. Physical exam revealed crackles at the mid lower lung fields bilaterally and 2+ lower extremity edema. EKG showed new ST inversions in lead 1, avF and V2. Troponin T was elevated to 0.11 ng/ml and proBNP was 21,246 pg/ml. Chest X Ray showed cardiomegaly with diffuse alveolar opacities. Transthoracic echocardiogram (TTE) revealed severely reduced left ventricular systolic function with LVEF of 25-29%, left ventricular regional wall hypokinesis and mildly reduced right ventricular systolic function. All findings were new compared to her last TTE 3 months prior, which showed preserved biventricular systolic function. Coronary angiography revealed no coronary artery disease. The patient was started on intravenous furosemide, and her home beta blocker and ARB were resumed. The patient’s Golimumab was discontinued given prior reports of TNF alpha inhibitor induced cardiomyopathy. Over the ensuing days, she was aggressively diuresed with improvement in oxygenation and ultimately discharged home. Three months after discontinuation of Golimumab, repeat TTE showed normalization of biventricular systolic function. Discussion: TNF alpha inhibitors have revolutionized the treatment of chronic immune mediated inflammatory diseases. Several TNF alpha inhibitors have been associated with cardiomyopathy, however there remains a paucity of evidence regarding cardiotoxicity with Golimumab. We now present, to our knowledge, the first reported case of reversible heart failure due to Golimumab in an 80 year old woman with RA. Golimumab, like other TNF alpha inhibitors, represents a historic advancement in the treatment of immune mediated inflammatory diseases. However, our case implicates this innovative drug in cardiotoxicity similar to other TNF alpha inhibitors. Further prospective studies are needed to establish a stronger correlation between Golimumab and cardiotoxicity.
NF‐κB signaling in inflammation and cancer
Authors: Tao Zhang, Chao Ma, Zhiqiang Zhang, Huiyuan Zhang, Hongbo Hu
Journal: MedComm (2021)

Abstract Since nuclear factor of κ‐light chain of enhancer‐activated B cells (NF‐κB) was discovered in 1986, extraordinary efforts have been made to understand the function and regulating mechanism of NF‐κB for 35 years, which lead to significant progress. Meanwhile, the molecular mechanisms regulating NF‐κB activation have also been illuminated, the cascades of signaling events leading to NF‐κB activity and key components of the NF‐κB pathway are also identified. It has been suggested NF‐κB plays an important role in human diseases, especially inflammation‐related diseases. These studies make the NF‐κB an attractive target for disease treatment. This review aims to summarize the knowledge of the family members of NF‐κB, as well as the basic mechanisms of NF‐κB signaling pathway activation. We will also review the effects of dysregulated NF‐κB on inflammation, tumorigenesis, and tumor microenvironment. The progression of the translational study and drug development targeting NF‐κB for inflammatory diseases and cancer treatment and the potential obstacles will be discussed. Further investigations on the precise functions of NF‐κB in the physiological and pathological settings and underlying mechanisms are in the urgent need to develop drugs targeting NF‐κB for inflammatory diseases and cancer treatment, with minimal side effects.
Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response
Authors: Chun-Yang Lin, Joshua Wolf, David C. Brice, Yilun Sun, Macauley Locke, Sean Cherry, Ashley H. Castellaw, Marie Wehenkel, Jeremy Chase Crawford, Veronika I. Zarnitsyna, Daniel Duque, Kim J. Allison, E. Kaitlynn Allen, Scott A. Brown, Alexandra H. Mandarano, Jeremie H. Estepp, Charles Taylor, Carmen Molina-Paris, Stacey Schultz-Cherry, Li Tang, Paul G. Thomas, Maureen A. McGargill, Aditya H. Gaur, James M. Hoffman, Tomi Mori, Elaine I. Tuomanen, Richard J. Webby, Hana Hakim, Randall T. Hayden, Diego R. Hijano, Walid Awad, Resha Bajracharya, Brandi L. Clark, Valerie Cortez, Ronald H. Dallas, Thomas Fabrizio, Pamela Freiden, Ashleigh Gowen, Jason Hodges, Allison M. Kirk, Ericka Kirkpatrick Roubidoux, Robert C. Mettelman, Jamie Russell-Bell, Aisha Souquette, James Sparks, Lee-Ann Van de Velde, Ana Vazquez-Pagan, Kendall Whitt, Taylor L. Wilson, David E. Wittman, Nicholas Wohlgemuth, Gang Wu
Journal: Cell Host & Microbe (2021)

SARS-CoV-2 infection causes diverse outcomes ranging from asymptomatic infection to respiratory distress and death. A major unresolved question is whether prior immunity to endemic, human common cold coronaviruses (hCCCoVs) impacts susceptibility to SARS-CoV-2 infection or immunity following infection and vaccination. Therefore, we analyzed samples from the same individuals before and after SARS-CoV-2 infection or vaccination. We found hCCCoV antibody levels increase after SARS-CoV-2 exposure, demonstrating cross-reactivity. However, a case-control study indicates that baseline hCCCoV antibody levels are not associated with protection against SARS-CoV-2 infection. Rather, higher magnitudes of pre-existing betacoronavirus antibodies correlate with more SARS-CoV-2 antibodies following infection, an indicator of greater disease severity. Additionally, immunization with hCCCoV spike proteins before SARS-CoV-2 immunization impedes the generation of SARS-CoV-2-neutralizing antibodies in mice. Together, these data suggest that pre-existing hCCCoV antibodies hinder SARS-CoV-2 antibody-based immunity following infection and provide insight on how pre-existing coronavirus immunity impacts SARS-CoV-2 infection, which is critical considering emerging variants.